Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator-Reference-Cited by-同舟云学术

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator

Published:2017-10-26 Issue:17 Volume:130 Page:1923-1933
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Vlachodimitropoulou Evangelia¹,Chen Yu-Lin²,Garbowski Maciej¹,Koonyosying Pimpisid¹,Psaila Bethan³,Sola-Visner Martha⁴,Cooper Nichola⁵,Hider Robert²,Porter John¹

Affiliation:

1. Haematology Department, University College London, London, United Kingdom;

2. Institute of Pharmaceutical Science, King’s College London, London, United Kingdom;

3. MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;

4. Paediatrics Department, Boston Children's Hospital, Boston, MA; and

5. Haematology Department, Hammersmith Hospital, Imperial College London, London, United Kingdom

Abstract

Key PointsELT is a powerful iron chelator, mobilizing iron and ferritin, reducing ROS, and restoring insulin production at clinically achievable levels. ELT enhances cellular iron chelation when combined with clinically available iron chelators through the shuttling of iron(III).

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/17/1923/1403086/blood740241.pdf

Reference53 articles.

1. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies;Williams;Clin Ther,2009

2. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS;Wire;Clin Ther,2012

3. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation;Roth

4. Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival;Kalota;PLoS One,2015

5. The Eltrombopag antitumor effect on hepatocellular carcinoma;Kurokawa;Int J Oncol,2015

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence;Annals of Hematology;2024-08-01

2. Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag;Frontiers in Immunology;2024-07-24

3. Customizable Zr-MOF nanoantidote-based multieffective arsenic detoxification and its extended low-toxic therapy;Acta Biomaterialia;2024-07

4. Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics;Hämostaseologie;2024-06-26

5. Molecular insights on Eltrombopag: potential mitogen stimulants, angiogenesis, and therapeutic radioprotectant through TPO-R activation;Platelets;2024-06-04